Compare BXMX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXMX | MNKD |
|---|---|---|
| Founded | 2004 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2004 |
| Metric | BXMX | MNKD |
|---|---|---|
| Price | $14.01 | $2.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.64 |
| AVG Volume (30 Days) | 142.4K | ★ 6.9M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $33.40 |
| Revenue Next Year | N/A | $16.48 |
| P/E Ratio | ★ N/A | $138.75 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $11.25 | $2.52 |
| 52 Week High | $15.00 | $6.51 |
| Indicator | BXMX | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 23.69 |
| Support Level | $13.70 | $2.52 |
| Resistance Level | $14.02 | $6.08 |
| Average True Range (ATR) | 0.21 | 0.36 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 15.00 | 8.04 |
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.